Iovance Biotherapeutics, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2023 | $195.7M | $780.4M | $114.9M |
| FY2024 | $200.0M | $910.4M | $115.7M |
| FY2025 | $214.6M | $913.2M | $163.1M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2023 | $195.7M | $780.4M | $114.9M |
| FY2024 | $200.0M | $910.4M | $115.7M |
| FY2025 | $214.6M | $913.2M | $163.1M |